Agenus (NASDAQ:AGEN) Posts Quarterly Earnings Results, Beats Estimates By $0.11 EPS

Agenus (NASDAQ:AGENGet Rating) released its quarterly earnings data on Tuesday. The biotechnology company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.11, MarketWatch Earnings reports. During the same period in the previous year, the company posted ($0.27) earnings per share.

Shares of AGEN stock opened at $1.51 on Thursday. The stock’s 50-day moving average price is $2.41 and its 200 day moving average price is $2.91. The company has a quick ratio of 2.12, a current ratio of 2.12 and a debt-to-equity ratio of 0.27. The stock has a market capitalization of $408.11 million, a PE ratio of -8.39 and a beta of 1.26. Agenus has a 52-week low of $1.50 and a 52-week high of $6.79.

AGEN has been the topic of several research reports. B. Riley dropped their price objective on Agenus from $11.00 to $8.00 in a report on Thursday, March 3rd. Zacks Investment Research lowered Agenus from a “hold” rating to a “sell” rating in a research report on Friday, March 4th. HC Wainwright boosted their price objective on Agenus from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, March 2nd. Finally, StockNews.com initiated coverage on shares of Agenus in a research report on Thursday, March 31st. They set a “hold” rating on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, Agenus currently has a consensus rating of “Hold” and a consensus price target of $8.75.

Several hedge funds have recently made changes to their positions in the business. State Street Corp increased its holdings in shares of Agenus by 71.9% in the fourth quarter. State Street Corp now owns 21,170,850 shares of the biotechnology company’s stock valued at $68,170,000 after purchasing an additional 8,857,832 shares during the period. Goldman Sachs Group Inc. increased its stake in Agenus by 125.8% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,823,329 shares of the biotechnology company’s stock valued at $9,091,000 after buying an additional 1,572,819 shares during the period. BlackRock Inc. raised its position in Agenus by 6.4% during the 4th quarter. BlackRock Inc. now owns 17,649,673 shares of the biotechnology company’s stock worth $56,831,000 after buying an additional 1,066,957 shares during the last quarter. Morgan Stanley lifted its stake in shares of Agenus by 341.5% in the 2nd quarter. Morgan Stanley now owns 1,284,065 shares of the biotechnology company’s stock worth $7,050,000 after acquiring an additional 993,231 shares during the period. Finally, Nuveen Asset Management LLC boosted its holdings in shares of Agenus by 45.3% in the fourth quarter. Nuveen Asset Management LLC now owns 2,583,129 shares of the biotechnology company’s stock valued at $8,007,000 after acquiring an additional 805,169 shares in the last quarter. Institutional investors own 65.88% of the company’s stock.

About Agenus (Get Rating)

Agenus Inc, a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.

Recommended Stories

Earnings History for Agenus (NASDAQ:AGEN)

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.